Premium
Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis
Author(s) -
Fu L. W.,
Yang L. Y.,
Chen W. P.,
Lin C. Y.
Publication year - 1997
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1997.00634.x
Subject(s) - pharmacokinetics , medicine , nephrotoxicity , lupus nephritis , pharmacology , bioavailability , oral administration , ciclosporin , creatinine , urology , gastroenterology , kidney , disease
Aims Neoral is a new microemulsion form of cyclosporin. Pharmacokinetic reports in children are scarce. Therefore, we performed a pharmacokinetic study between Cyclosporin A (CsA) capsules and Neoral in paediatric patients with lupus nephritis. Methods A single 5 mg kg −1 dose orally of either CsA capsules or Neoral was given to 10 paediatric patients (serum creatinine<1.5 mg dl −1 ). CsA whole blood levels were measured for 24 h post‐dose by h.p.l.c. Results Neoral had a higher C max and AUC(C max : 943±176 ng ml −1 ; AUC: 4612±785 ng ml −1 h) than those of the CsA capsules (C max : 697±187 ng ml −1 ; AUC: 3483±873 ng ml −1 h; P<0.05). There was no difference in t max and t 1/2,z between the two groups. Conclusions CsA Neoral had improved absorption and bioavailability, which is similar to what is reported in adults. However, interpatient variability still existed. Careful drug monitoring and dose adjustment should be performed during treatment to avoid nephrotoxicity, especially in lupus nephritis.